Navigation Links
Novel cytokine protects mice from colitis
Date:8/23/2011

Inflammatory bowel disease (IBD), which affects more than 1 million patients in North America, results from an uncontrolled immune response triggered by environmental factors, such as bacteria, in people genetically predisposed to the disorder. Ulcerative colitis, or inflammation of the lining of the colon, is one such condition.

The aberrant immune response found in IBD is prompted by different cytokines small signaling proteins secreted by various cells, including immune cells that activate the immune system, causing chronic inflammation.

Now researchers led by Jess Rivera-Nieves, MD, of the Inflammatory Bowel Disease Center, Division of Gastroenterology at the University of California, San Diego School of Medicine, have discovered that expression of a newly identified human cytokine Interleukin 37 (IL-37) protects mice from colitis. The study will be published this week in Proceedings of the National Academy of Sciences (PNAS).

IL-37 is a member of the IL-1 family and functions as an inhibitor of innate inflammation and immunity. While most molecules in the IL-1 family appear to promote an inflammatory response, IL-37 modulates or downgrades inflammation.

Charles A. Dinarello, MD, from the University of Colorado, recently expressed human IL-37 in lab mice, which do not have an orthologue, or similar molecule, for this particular cytokine. Nonetheless, IL-37 works the same in both mice and humans. The mice were then fed water containing dextran sulfate sodium (DSS), a substance that induces colitis, to see whether IL-37 provided protection from intestinal inflammation.

It did. "While we still don't understand its mechanism of action, our hope is that, in the future, scientists may be able to engineer cells to overproduce IL-37 and use it to treat or control an overactive immune system in humans," said Rivera-Nieves.

That would represent a major advance in treating IBD, particularly for the 30 to 50 percent of IBD patients for whom highly effective biological therapies tumor necrosis factor inhibitors don't work, or for an even larger percentage of patients whose symptoms eventually return.


'/>"/>

Contact: Debra Kain
ddkain@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert

Related medicine news :

1. FDA Approves Novel Melanoma Drug
2. St. Michaels North America first to use novel blood-cleaning procedure for kidney transplant
3. Novel DNA sequencer for MDCs systems biology
4. Novel Virus Jumped From Monkeys to Humans, Researchers Find
5. Novel combined therapy extends life, diminishes pain in brain cancer patients
6. Experiment aboard shuttle Atlantis will test novel therapy to build bone during space travel
7. Study uncovers novel genetic variation linked to increased risk of sudden cardiac arrest
8. Novel analysis method organizes genomic cancer data
9. Scientists identify a novel mechanism for evolution of highly aggressive cancers
10. CSHL structural biologists reveal novel drug binding site in NMDA receptor subunit
11. HIV-infected donors present novel source of organs for HIV-infected transplant candidates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2017)... Edmonton, AB (PRWEB) , ... July 21, 2017 , ... ... a life insurance brokerage firm servicing Albertans,” says owner and licensed broker Nerissa McNaughton. ... health insurance can be difficult, but it is a very necessary conversation. I make ...
(Date:7/21/2017)... ... , ... "As a doctor of lung medicine managing chest diseases for more ... said an inventor from Center Valley, Pa. "My idea is to improve the device ... the patent-pending PLEURAL SAFE-t-STAT CATHETER KIT to offer an efficient means of draining pleural ...
(Date:7/21/2017)... Augusta, GA (PRWEB) , ... July 21, 2017 , ... ... is teaming up with the Epilepsy Foundation in a community wide charity event with ... region. , Delaney Sunde, a young local woman who lives with epilepsy, recently launched ...
(Date:7/21/2017)... Minnesota (PRWEB) , ... July 21, 2017 , ... ... BWBR recently were selected to renovate and improve the Ramsey County Medical Examiners ... adjacent to Regions Hospital, the $2.5 million project is scheduled to start in ...
(Date:7/21/2017)... ... July 21, 2017 , ... Hospital M&A activity slowed in the second quarter ... hospital acquisitions rose to 23 in the second quarter, up 15% from the 20 ... 20 announced deals in the year-ago second quarter. Only four of the transactions disclosed ...
Breaking Medicine News(10 mins):
(Date:7/5/2017)... Wash. , July 5, 2017   BioLife ... leading developer, manufacturer and marketer of proprietary clinical grade ... cryopreservation freeze media ("BioLife"), today announced that it ... its debt holder and largest shareholder, to modify its ... Pursuant to the modification, WAVI agreed to exchange ...
(Date:6/30/2017)... SAN DIEGO , June 30, 2017  AVACEN Medical (AVACEN) ... Access Journal. The research describes the use of its AVACEN ... by those suffering from fibromyalgia. ... AVACEN Medical ... Fibromyalgia is characterized by chronic widespread pain. It affects approximately 200 to ...
(Date:6/27/2017)... 27, 2017   NuEyes (NuEyes Technologies Inc.) today ... fuel its growth in helping the legally blind live more ... Group), the leading developer of augmented, virtual and mixed reality ... The undisclosed funding amount was provided by strategic partners ... with offices in Abu Dhabi , ...
Breaking Medicine Technology: